Arm Holdings plc - American Depositary Shares (ARM)

Arm's royalty model compounds reliably across billions of devices. TSMC's factories build the chips that power every major AI system in the world. Both are essential, but only one is truly irreplaceable.

Where you place a Dexcom G7 sensor can make a difference in comfort, sensor adhesion, and performance. If you are using the G7 for the first time, it is no

The two companies will combine to complete and deploy a tokenized stock trading platform.

Arm Holdings shares jumped 17% on reports of a Meta custom-chip partnership and a $2 billion AI processor target, though elevated valuation multiples and foundry supply constraints temper near-term upside.

The Pentagon expanded General Motors' contract to build lightweight troop carriers.

Wall Street is finally recognizing the potential of Muse.

Meta's Muse could usher in a wave of agentic AI-driven growth for chipmakers.

Arm powers 99% of smartphones with 22.8% revenue growth, while NVIDIA's $215.9 billion in revenue and 55.6% margins dominate AI infrastructure.

Buyback announcements are cheap headlines. "$10 billion share repurchase program" sounds impressive regardless of whether the company can actually afford i

AI and semiconductor stocks are richly valued, while a couple of the leading cryptocurrencies are just starting to pick up steam.

Sponsors rarely struggle to find advice. They struggle to find advice that holds up in front of an FDA review team, a slow-enrolling site network, and an i

Located along one of Gurugram’s established luxury residential corridors, Max Estate 59 is an upcoming residential development planned in Sector 59, close

Arm trades at a 125x forward P/E versus ASML's 27.9x, yet both command premium valuations for their monopolistic positions in mobile and chip manufacturing, respectively.

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Zii

One designs chips; the other manufactures them, and their valuations tell starkly different stories about growth versus value.

Boeing's slow progress is not being recognized yet by the market.

Is Arm still an under-the-radar AI winner? Wall Street is catching on fast.

CytoDyn (OTCMKTS:CYDY) Chief Financial Officer Robert E. Hoffman outlined the company’s clinical-development plans for leronlimab, a CCR5-targeting humanized monoclonal antibody being studied in metastatic colorectal cancer, triple-negative breast cancer and other solid tumors. Speaking at the Life

Whether investors realize it or not, the ruling is huge for Google's parent company and its stock.

Astera Labs is riding explosive demand for AI connectivity chips with gross margins above 70%. Arm is compounding royalty revenue across billions of devices while its data center business accelerates.

Arm's licensing model generates 18.4% net margins with minimal debt, while Intel battles a net loss and negative free cash flow amid its foundry pivot.

GE Vernova is posting record orders and dramatically raising its free cash flow outlook. NextEra is executing steadily but navigating a major merger that won't close for another year.

The chipmaker is racing to meet the surging demand for its new AI chips.